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744 | Nanoscale, 2013, 5, 744–752Self-assembled magnetic theranostic nanoparticles for
highly sensitive MRI of minicircle DNA delivery†
Qian Wan,‡a Lisi Xie,‡a Lin Gao,a Zhiyong Wang,*a Xiang Nan,a Hulong Lei,a
Xiaojing Long,a Zhi-Ying Chen,b Cheng-Yi He,b Gang Liu,d Xin Liua
and Bensheng Qiu*ac
As a versatile gene vector, minicircle DNA (mcDNA) has a great potential for gene therapy. However, some
serious challenges remain, such as to effectively deliver mcDNA into targeted cells/tissues and to non-
invasively monitor the delivery of the mcDNA. Superparamagnetic iron oxide (SPIO) nanoparticles have
been extensively used for both drug/gene delivery and diagnosis. In this study, an MRI visible gene
delivery system was developed with a core of SPIO nanocrystals and a shell of biodegradable stearic
acid-modified low molecular weight polyethyleneimine (Stearic–LWPEI) via self-assembly. The Stearic–
LWPEI–SPIO nanoparticles possess a controlled clustering structure, narrow size distribution and
ultrasensitive imaging capacity. Furthermore, the nanoparticle can effectively bind with mcDNA and
protect it from enzymatic degradation. In conclusion, the nanoparticle shows synergistic advantages in
the effective transfection of mcDNA and non-invasive MRI of gene delivery.Introduction
Gene therapy is a very exciting medical frontier that uses
transgenes to treat or prevent various diseases.1 At present,
standard plasmids are the mostly used gene vectors in many
clinical trials.2 However, this class of DNA vectors oen lose
transgene expression shortly aer delivery due to the silencing
and induction of cytotoxic cell death mechanisms imbedded in
their bacterial backbones.3 Recently, minicircle DNA (mcDNA)
has attracted a lot of attention, because it is free of the detri-
mental bacterial sequences, which makes it excellent in terms
of bio-safety and allows for persistent transgene expression.4–7
Nevertheless, the lack of highly effective mcDNA delivery tech-
niques is still an obstacle for the translation of this promising
DNA vector into clinical applications. In addition, it is also
necessary to develop non-invasive imaging techniques to
monitor gene delivery in vivo.8medical Imaging, Institute of Biomedical
utes of Advanced Technology, Chinese
China. E-mail: zy.wang@siat.ac.cn; bs.
l: +86-755-86392268
titute of Biomedicine and Biotechnology,
ology, Chinese Academy of Sciences,
shington School of Medicine, USA
tional Medicine, School of Public Health,
tion (ESI) available. See DOI:Molecular imaging is an emerging technology that enables
the visualization of molecular pathways in cells or tissues
without perturbation.9 Since magnetic resonance imaging
(MRI) can provide excellent spatial resolution of so tissues and
deep tissue penetration without radiation, it is one of the best
modalities for molecular imaging. However, the sensitivity of
MRI is relatively low as compared with positron emission
tomography (PET) and optical imaging.10 Fortunately, the
sensitivity can be improved with the help of MRI contrast
agents.10,11 Superparamagnetic iron oxide (SPIO) nanoparticles,
one kind of MRI contrast agents, exert a strong effect on
shortening the spin–spin relaxation (T2) time. Meanwhile,
SPIOs can be used as functional carriers of therapeutic genes
and/or drugs.12,13 Recently, high-quality SPIO nanocrystals with
a uniform size and excellent crystal structure have been
synthesized in the organic phase.14 However, surface modica-
tion of these nanoparticles is still necessary in order tomaintain
their stability in a physiological environment and so that they
can be designed as SPIO-based gene delivery vehicles.
Polyethylenimine (PEI), an effective gene transfection agent,
can compactly bind with nucleic acids, protect genes from
degradation and enter cells through rapid endocytosis.15–17
Compared with high molecular weight PEI (HWPEI), low
molecular weight PEI (LWPEI) exhibits lower cytotoxicities as
well as lower transfection efficiencies.18 In this study, we used
stearic acid graed LWPEI to encapsulate SPIO nanocrystals to
form a biocompatible nano-scopic therapeutic system (Stearic–
LWPEI–SPIO) via self-assembly. The Stearic–LWPEI–SPIO
nanoparticles are not only capable of stably binding, protecting,














































View Article Onlineclustering nanostructure for the ultra-sensitive MRI of gene
delivery. Through systemic validation, this nanoparticle we have
developed has a great potential as an MRI visible gene delivery
vehicle.Materials and methods
Materials
Benzyl ether (99%), 1,2-hexadecanediol (97%), oleic acid (90%),
oleylamine (>70%), and iron(III) acetylacetonate were purchased
from Aldrich Chemical Company. Stearic acid, N,N-carbon-
yldiimidazole (CDI) and polyethylenimine (Mw 600 g mol
1,
PEI600) were obtained from Aladdin Reagent Co., China. The
mcDNA expressing luciferase was made using the plasmid
pMC.RSV.Luc.SVpA carrying the luciferase cDNA (D-luciferin,
Gold Bio Technology) and minicircle producer E. coli strain
ZYCY10P3S2T per the previous reported method.7 Phosphate
buffered saline (PBS), DMEM medium, ethidium bromide and
agarose gel were purchased from Gibco (USA). The humanMCF-
7 cancer cells were obtained from the American Type Culture
Collection (ATCC). A Cell Counting Kit-8 assay was purchased
from Dojindo, Kumamoto Japan. All other chemicals are of AR
grade, and used without further purication. BALB/c and BALB/
c nude male mice (6 weeks age, average body weight 20 g) were
purchased from Guangdong Province Laboratory Animal Center
(Guangzhou, China). In the experiments, all animal protocols
were approved by the Institutional Animal Care and Usage
Committee. All experiments were performed in compliance
with the relevant laws and institutional guidelines.Synthesis and characterization of the SPIO nanocrystals
The detailed synthetic method of the SPIO nanocrystals has
been described in a previous publication.14 Briey, Fe(acac)3
(2 mmol), 1,2-hexadecanediol (10 mmol), oleic acid (6 mmol),
and oleylamine (6 mmol) were mixed together in benzyl ether
(20 mL). Then the mixture was heated up to 300 C under argon
for 1 h. The puried SPIO nanocrystals were obtained via
washing three times with ethanol and hexane, and then nal
dispersing in hexane.
The structural integrity of the nanocrystals was assessed via
transmission electron microscopy (TEM, FEI Tecnai 20). The
crystal structure of the nanocrystals was determined through
selected area electron diffraction (SAED) and high-resolution
transmission electron microscopy (HRTEM) analysis. The
measured lattice spacing was compared to the standard atomic
spacing indexes of Fe3O4 from the JSPDS (PDF) database. To
obtain the size distribution, the SPIO nanocrystals dispersed in
hexane were characterized through dynamic light scattering
(DLS) measurements (Zetasizer Nano system, Malvern).Synthesis and characterization of stearic acid-modied
polyethylenimine
The preparation of Stearic–LWPEI was carried out following a
previously published protocol.19 Under argon protection, CDI
(0.35 g) was suspended in dry chloroform solvent (20 mL), then
stearic acid (0.6 g) was added. The obtained solution was reactedThis journal is ª The Royal Society of Chemistry 2013at room temperature for 2 h. Then the carboxy-terminal activated
stearic acid was transferred into a ask containing 0.7 g of
PEI600 and 20mL of dried chloroform. Themixture was allowed
to react for 24 h at room temperature. The puried product,
Stearic–LWPEI, was obtained as a white solid aer precipitation
in cold ether with a yield of 65% and then conrmed by 1H NMR
in CDCl3 (Bruker 500 MHz, Bellerica, MA).
The pH buffering capabilities of Stearic–LWPEI, PEI600 and
puried water were determined via acid–base titration over a
biophysical pH range from 7.5 to 5.20 First, 15 mL of sample
solution was prepared with 0.3 mmol amine group. Then, the
solution was titrated with 10 mL increments of 1 N HCl and the
pH value was measured using a pH-meter (FE30, METTLER) at 2
min intervals. Then, the curve of the pH titration for each
sample was generated.
Preparation and characterization of the Stearic–LWPEI–SPIO
nanoparticles
To transfer the SPIO nanocrystals from organic solvent into
water, 5 mg Stearic–LWPEI was mixed with the SPIO nano-
crystals (10 mg) in chloroform. With sonication, the organic
solution was slowly added to water. Then the mixture was shook
for 24 h. The water dispersed Stearic–LWPEI–SPIO nano-
particles were prepared aer removing the chloroform via rotary
evaporation. The nanoparticles were characterized through
DLS, zeta potentials and TEM.
MR imaging capacity of the Stearic–LWPEI–SPIO
nanoparticles
Elemental analyses of iron from the Stearic–LWPEI–SPIO
nanoparticles were measured using the atomic absorption
spectrum (AAS, Analytik Jena ZEEnit 700 P). The T2 relaxivity of
the nanoparticles was measured by using a 3T clinical MR
scanner (Siemens) at room temperature as described.21,22 The
T2-weighted images were obtained by using a spin echo pulse
sequence with a long repetition time (TR ¼ 5000 ms) and
various echo times (TE) from 12 to 150 ms. Then, the T2 relax-
ivity, R2, was calculated by tting the curve of the signal inten-
sities versus various TEs, presented with the iron concentration
(mM).
Preparation and characterization of the Stearic–LWPEI–SPIO/
mcDNA nanocomplexes
Following the established methods,13,23 the nanocomplexes of
Stearic–LWPEI–SPIO/mcDNA with different N/P ratios (N/P ratio
from 1 to 20), were prepared by mixing an appropriate amount
of Stearic–LWPEI–SPIO nanoparticles with mcDNA in PBS
solution. The obtained nanocomplexes were incubated at room
temperature for 20 min. The binding efficacy was characterized
through agarose gel electrophoresis. Herein, the samples were
added to an appropriate amount of DNA loading buffer. Gel
electrophoresis was carried out at 100 V for 20 min. Then, the
gel was subsequently imaged using a Dolphin-Doc Plus gel
documentation system (Wealtec). Furthermore, the
Stearic–LWPEI–SPIO/mcDNA nanocomplexes were character-














































View Article OnlineFor the DNase stability assay, the Stearic–LWPEI–SPIO/
mcDNA nanocomplexes (N/P ratio of 20) were incubated with
DNase I at 0.1 U concentration for 10 min at 37 C. The resulting
samples were treated with heparin and then subjected to elec-
trophoresis as described above.Cell culture and transfection
Human MCF-7 cancer cells were cultured in DMEM medium
containing glutamine supplemented with 10% FBS and antibi-
otics. Cells (5  103 per well) were seeded in 96-well plates
before the experiment. Then the samples (PEI600/mcDNA,
Stearic–LWPEI/mcDNA and Stearic–LWPEI–SPIO/mcDNA
complexes) with different N/P ratios were added into each well
with 20 mL of the transfection medium containing 0.25 mg
mcDNA. Aer 6 h, the medium was replaced with fresh DMEM
medium. The luciferase expression in MCF-7 cells was evalu-
ated 48 h aer transfection using a Xenogen IVIS-100 system
(Caliper Life Sciences) with the addition of 100 mL D-luciferin
(300 mg mL1) per well. The total protein in each well was
determined using a BCA protein assay kit (Thermo).
Aer transfection, the cytotoxicities of the samples were
evaluated using the Cell Counting Kit-8 assay per the recom-
mended protocol from the manufacturer (Dojindo, Kumamoto
Japan), which measured the absorbance at 450 nm using a
multimode plate reader (Synergy 4, BioTek). Then iron uptake
was analyzed for each group based on our established
methods.21,24 Aer transfection, the cells were reseeded in a new
6-well plate for 6 h, then Prussian blue staining was analyzed for
each sample.MRI study of transfected cells
At the end of transfection, cells were washed three times with
PBS and harvested. Various numbers of cells were dispersed in
gelatin (1%) inside microcentrifuge tubes for MRI analysis.22,25
MR imaging of these cells was carried out on a 3T clinical MR
scanner with a small animal coil. T2-weighted MR images were
acquired using the following parameters: multicontrast-spin
echo (se-mc) sequence, TR ¼ 5000 ms, TE from 10.6 to 53 ms,
FOV ¼ 25  62 mm, and slice thickness ¼ 1.0 mm. The signal
intensity of the T2-weighted MRI was used to calculate the T2
value of each sample through an analysis program provided by
the MRI scanner. The MRI signal of the transfected cells was
measured against a background of blood in order to get an idea
of the signal-to-noise ratio in the body (see ESI for details†).
For in vivo MR imaging, the transfected cells (0.05 mL; 5 
105 cells) were injected subcutaneously at the right scapular of a
BALB/c nude mouse, and the same amount of non-transferred
cells were injected in the other side (see ESI for details†).Fig. 1 Characterization of SPIO nanocrystals: (A) DLS analysis of magnetite
nanocrystals in hexane; (B) TEM images of the synthesized iron oxide nanocrystals
(scale bars: 40 nm); (C) measured lattice spacing, d (Å), based on the rings in (D),
and the standard atomic spacings for Fe3O4 along with their respective hkl
indexes from the PDF database.Statistical analysis
The data was statistically analyzed through SPSS soware
(version 13.0, SPSS Inc) and P < 0.05 was considered to be
statistically signicant.746 | Nanoscale, 2013, 5, 744–752Results
Characterization of SPIO nanocrystals and Stearic–LWPEI
The size distribution of the synthesized SPIO nanocrystals was
characterized through DLS and TEM. As shown in Fig. 1A and B,
the monodispersed nanoparticles had a narrow size distribu-
tion of 10.4  2.8 nm. Crystal structure information of the SPIO
nanocrystals was obtained using HRTEM and SAED (Fig. 1C and
D). The HRTEM image of an isolated Fe3O4 nanoparticle
(Fig. 1C) showed that the distance between two adjacent planes
was approximately 2.98 Å, which corresponds to the (220)
planes in spinel-structured Fe3O4. In the SAED image (Fig. 1D),
the obtained index of lattice spacing based on the rings was
compared to the known lattice spacing for bulk Fe3O4 along
with their respective hkl indexes from the PDF database. The
synthesized nanocrystals exhibited a similar crystal structure to
magnetite nanoparticles. However, these high-quality nano-
particles are unsuitable for biomedical applications, because
they are stabilized with a layer of hydrocarbon and dispersed in
organic solvent.14 Thereby, surface modication of the hydro-
phobic nanoparticles is necessary.26
In this study, the amphiphilic macromolecule Stearic–
LWPEI was used to perform the phase transfer process. Stearic–
LWPEI was prepared by direct conjugation of stearic acid with














































View Article Onlinecarboxylic acid imidazolide which condensed with the amino
group to form an amide linkage.27 The partial modication of
Stearic–LWPEI was conrmed by 1H NMR (CHCl3): d (ppm)
0.86–0.89 [t, –CH2CH2(CH2)15CH3], 1.25 [br, –CH2CH2(CH2)15-
CH3], 1.62 [br, –CH2CH2(CH2)9CH3], 2.18 [br, –CH2CH2(CH2)9-
CH3], 2.39–3.3 [m, –CH2CH2NH–, –CH2CH2N–, –CH2CH2NHCO–,
–CH2CH2NHCO–]. This result is in agreement with the previous
data.19 It yielded a sample with a 14% degree of substitution.
It is well known that DNA–nanoparticles enter cells via
endocytosis and through the low pH environment in the endo-
some during transfection, so a “proton sponge” capacity is
necessary for gene vectors to escape from the endosome.28
Herein, the well accepted “proton sponge” effect of the Stearic–
LWPEImacromolecule was determined via acid–base titration.29
As shown in Fig. 2A, Stearic–LWPEI underwent a minimal
pH value change when the equivalent amount of HCl was
added, as compared with the controlled groups, PEI600 and
water. To our surprise, the modied PEI exhibited a higher
“proton sponge” capacity compared with its homopolymer,
PEI600 (Fig. 2B), at the same mole concentration of the amineFig. 2 Characterization of Stearic–LWPEI–SPIO nanoparticles. (A) Buffering capacity
total [H+] required at the pH range from 7.5 to 5 (n ¼ 3); (C) DLS analysis of SPIO na
(solid line); (D) T2 relaxation rate (1/T2, s
1) as a function of iron concentration (mM)
sequence: TR ¼ 5000 ms, TE ¼ 30 ms) of the Stearic–LWPEI–SPIO nanoparticles.
This journal is ª The Royal Society of Chemistry 2013groups. A similar result was observed with PEG or cholesterol
modied PEI.20,30 These acid–base titration results indicate that
the Stearic–LWPEI macromolecule possesses an excellent
buffering capacity.
Self-assembly of the Stearic–LWPEI–SPIO nanoparticles
The amphiphiles were used to form Stearic–LWPEI–SPIO
nanoparticles via a self-assembly method. The DLS measure-
ments of these nanoparticles showed an average hydrodynamic
size of 63  20 nm (PDI ¼ 0.138) (Fig. 2C) and a positive zeta
potential close to +57 mV in deionized water (Fig. 3C). The zeta
potential could affect the stability of aqueous colloidal disper-
sions. Usually, if the surface charge is greater than 30 mV,
particles are less likely to undergo aggregation into a larger
one.31 In our research, these Stearic–LWPEI–SPIO nanoparticles
with a high surface zeta potential were stable and did not show
a non-measurable size increase at a wide range of pH values
from 5 to 8 in 0.0067 M PBS or in the salt solution with NaCl
concentrations from 0.9% to 1 M aer 24 h incubation at room
temperature (data not show here). The lower pH and saltof Stearic–LWPEI and PEI600. Titration curves over the pH range from 7.5 to 5; (B)
nocrystals in hexane (dashed line) and Stearic–LWPEI–SPIO nanoparticles in water
for Stearic–LWPEI–SPIO nanoparticles; (E) T2-weighted MRI images (3T, spin-echo
Nanoscale, 2013, 5, 744–752 | 747
Fig. 3 Physical characterization of Stearic–LWPEI–SPIO/mcDNA nanocomplexes. (A) The gel electrophoretic retardation analysis of mcDNA complexed with Stearic–
LWPEI–SPIO nanoparticles; (B) zeta potential and (C) average diameter of the Stearic–LWPEI–SPIO/mcDNA nanocomplexes at various N/P ratios; (D) TEM analysis of the
Stearic–LWPEI–SPIO/mcDNA nanocomplexes at a N/P ratio of 20 (scale bars: 200 nm). (E) DNase stability analysis of mcDNA on the Stearic–LWPEI–SPIO nanoparticles.














































View Article Onlinesensitivities of the Stearic–LWPEI–SPIO nanoparticles are
probably correlated to the chain exibility and reversible
protonation of PEI.32
To understand how the Stearic–LWPEI–SPIO nanoparticles
perform as molecular imaging agents, we studied their contrast
effect using an 3.0 T MRI. SPIO-based MR contrast agents can
shorten the T2 (spin–spin) relaxation time, herein, the spin–spin
relaxivity R2 (R2 ¼ 1/T2) has been used to represent the degree of
the T2 contrast effect.33 An imaging agent with better contrast
effect would display a higher R2 value. In the experiments, the R2
of the Stearic–LWPEI–SPIO nanoparticles was 328.85 Fe
mM1s1 (Fig. 2D). We compared the MRI signal intensities at
different iron concentrations, which revealed that the T2-
weighted signal intensity decreased remarkably with an increase
of the Fe concentration (Fig. 2E). We measured the imaging
sensitivity of the nanoparticles at theMRI signal intensity which
is decreased to 50% of that for pure water in the T2-weighted
images at 3T (spin-echo sequence: TR¼ 5000 ms, TE¼ 55ms).24
The sensitivity limit was about 1.5 mg mL1 Fe. This high sensi-
tivity is essential for molecular imaging applications.Characterization of the Stearic–LWPEI–SPIO/mcDNA
nanocomplexes
The mcDNA complexation ability of the Stearic–LWPEI–SPIO
nanoparticles was conrmed using agarose gel electrophoresis
analysis. It is well known that a nucleic acid can bind to a748 | Nanoscale, 2013, 5, 744–752polycation by electrostatic interaction and then lose the
mobility in an electric eld. When the N/P ratio was higher than
2, the migration capability of mcDNA was completely blocked,
indicating the complete complexation of mcDNA (Fig. 3A). The
stable complexation would protect DNA by sterically blocking
the access of DNA-degradation enzymes in the endosome.34
In previous reports, the size of the nanoparticles could inu-
ence cellular internalization,35,36 and the positive charge of nano-
particles would enhance interactions with the anionic cell
membrane.37 In this study, the hydrodynamic size and zeta
potential of the Stearic–LWPEI–SPIO/mcDNA nanocomplexes
depended on the N/P ratio. The zeta potential of the nano-
complexes decreased from +50 mV to +32 mV when the N/P ratio
decreased from 20 to 5 (Fig. 3B). Meanwhile, the effective hydro-
dynamic diameter increased (Fig. 3C). Herein, the smallest
diameter was 67  24 nm (PDI ¼ 0.192) at a N/P ratio of 20. The
TEMimages showed that thenanocomplexes (N/P ratio of 20)were
spherical, monodispersed, and maintained a compact clustering
feature (Fig. 3D). Gene vectors need protection against enzymatic
degradation andmigration into thenucleus.34 In this study, naked
mcDNAandtheStearic–LWPEI–SPIO/mcDNAnanocomplexesat a
N/P ratio of 20 were incubated with DNase I at 37 C for 10 min.
FreemcDNAwas rapidly degraded byDNase I. Contrarily, mcDNA
on the nanoparticles was protected, and could be released when
heparin was added (Fig. 3E). These results demonstrated that the
mcDNAon thenanoparticles couldbeprotected fromdegradation
and could undergo controlled release.This journal is ª The Royal Society of Chemistry 2013















































View Article OnlineGene transfection
In vitro transfection experiments were performed to evaluate the
mcDNA delivery applicability of the Stearic–LWPEI–SPIO
nanoparticles. The nanoparticles and cationic macromolecules
were used at N/P ratios of 5, 10 and 20 with the same quantity of
mcDNA. The gene transfection efficiency was asserted by
measuring the bioluminescence imaging (BLI) signal intensity
(Fig. 4).
The Stearic–LWPEI–SPIO and Stearic–LWPEI nanoparticles
showed a slightly enhanced transfection effect. Nevertheless,
the low molecular weight PEI600 was an inferior agent for gene
transfection. It is believed that the hydrophobic modication of
PEI would increase the plasmid DNA delivery into cells as
reported.38,3
We evaluated the iron content in cells to assess the cellular
uptake of the nanocomplexes at different N/P ratios. As shown
in Fig. 5, the iron content was about 2.1 pg (Fe) per cell at a N/P
ratio of 20, which was higher than 0.9 and 1.4 pg (Fe) per cell at
N/P ratios of 5 and 10, respectively. Furthermore, the results of
the Prussian blue staining was consistent with the iron analysis,
and showed a remarkable higher iron accumulation in the
cytoplasm at a N/P ratio of 20. Conversely, few cells were stained
blue in the control group (Fig. 6).
MRI study of transfected cells
With the help of contrast agents, molecular MR imaging has
been used to monitor gene delivery for therapy.13 In Fig. 7, the
transfected cells exhibited a signicantly decreased signalFig. 4 (A) The luciferase activity with MCF-7 cells transfected by the Stearic–
LWPEI–SPIO/mcDNA nanocomplexes, Stearic–LWPEI and PEI600 at various N/P
ratios; (B) optical images of luciferase gene expression.
This journal is ª The Royal Society of Chemistry 2013intensity in the T2-weighted images compared with the control
images. The transfected cells shortened the transverse proton
relaxation time (T2) and resulted in darkened T2-weighted
images. These cells corresponded to lower signal intensities at
higher N/P ratios, because of a higher cellular internalization
rate of the nanocomplexes. This data was in accordance with
the results of iron content in Fig. 5. Furthermore, prolonging
the echo time (TE) can increase the signal contrast between
transfected cells (N/P ratio of 20) and control ones (Fig. 8). At an
TE of 53 ms (millisecond), the signal intensity of the controlled
cells (SIC) was 51.3 times that of the transfected cells (SIT),
compared to the 4.8 times at a shorter TE (10.6 ms).
To determine the MRI sensitivity, the transfected cells with
numbers from 6 103 to 5 105 cells were dispersed in gel with
a nal volume of 100 mL. In Fig. 9, the T2 value decreased from
157 to 13.8 ms (millisecond) with the increase of the cell
numbers. Furthermore, the lowest concentration of transfected
cells were even visible against a background signal from iron in
blood (Fig. S1†). Correspondingly, the in vivo T2-weighted image
showed that the labeled cells were visible as a low signal
intensity area at the injection site (Fig. S2A†). The level of
exogenous gene expression in the labeled cells could be
analyzed via in vivo bioluminescence imaging (Fig. S2B†). It is
possible for the cells transfected with the Stearic–LWPEI–SPIO/Fig. 6 Prussian blue stains of the control MCF-7 cells (A) and cells transfected by
Stearic–LWPEI–SPIO/mcDNA nanocomplexes with different N/P ratios at 5 (B), 10
(C) and 20 (D), (scale bars: 100 mm).
Nanoscale, 2013, 5, 744–752 | 749
Fig. 7 T2 values (3T, spin echo acquisition) of the Stearic–LWPEI–SPIO/mcDNA
nanocomplex transfected cells (2.5  103 cells per mL) at different N/P ratios in
gelatin phantom in microcentrifuge tubes. Insets: cross-section MR images of the
corresponding tubes under TR ¼ 5000 ms, TE ¼ 53 ms.
Fig. 8 T2-weighted imaging (3T, TR ¼ 5000 ms, TE ¼ 10.6, 21.2, 31.8, 42.4, 53
ms) of the control cells and cells transfected with the Stearic–LWPEI–SPIO/mcDNA
nanocomplexes at a N/P ratio of 20 (2.5  103 cells per mL). The ratios of signal
intensities of the control samples (SIC) and the test ones (SIT) are shown with
different TE times.
Fig. 9 T2 values of the Stearic–LWPEI–SPIO/mcDNA nanocomplexes (N/P ratio
of 20) transfected cells as a function of cell number in a total volume of 100 mL. 3T,
se-mc acquisition, insets: cross-section MR images of the corresponding tubes:
TR ¼ 5000 ms, TE ¼ 53 ms.














































View Article OnlinemcDNA nancomplexes to provide noticeable signal contrast
compared to other cells during cell tracking on a clinical 3T
MRI. This MRI visibility will enable the monitoring of the gene
transfection procedure in a non-invasive and dynamic mode.
Cytotoxicities
Low cytotoxicity is another requirement for gene vectors. Aer
transfection, the metabolic activity within MCF-7 cells was
measured via the CCK-8 assay (Fig. 10). In the experiment, the
results indicated that the Stearic–LWPEI–SPIO/mcDNA nano-
complexes had little cytotoxicity at N/P ratios of 5 and 10 (P >
0.05). At a N/P ratio of 20, Stearic–LWPEI–SPIO showed 94.5%
metabolically active cell viability (*, P value ¼ 0.037) compared
with the control group. In the group of Stearic–LWPEI, the
viability rate was 85.8% (**, P value < 0.001). However, at all N/P
ratios, the PEI600 group showed a minimal toxic effect. The
cytotoxicity of the Stearic–LWPEI macromolecule was inferred
due to the enhancement of the interaction with either the
plasma membrane or components in the cells that affected
metabolic activity and induced cell injury.39
Discussion
Gene therapyhasbeenregardedasapromising treatment inmany
diseases. In the past decade, various non-viral gene vectors have
been developed for gene therapy. However, there is a lack of non-
invasive methods to evaluate the kinetics and biodistribution of
gene vectors in the body. Recently, molecular MR imaging has
enabled the visualizationof themolecular process in vivoandnon-
invasively. Thus, gene vectors integrated with imaging probes
have attracted great attention for personalized gene therapy. In
this study, the ultimate goal is to develop a MRI visible gene
delivery vectorwithhigh imaging sensitivity, biocompatibility and
high gene transfection efficiency. Traditionally, the colloidal
magnetic oxide nanocrystals are synthesized throughFig. 10 Cell viability profile of the Stearic–LWPEI–SPIO nanoparticles, Stearic–
LWPEI and PEI600 treated MCF-7 cells at different N/P ratios (C: control; * and **:
significantly different from the control group through statistical analysis. *P ¼
0.035; **P < 0.001).














































View Article Onlineprecipitationof ferric and ferrous ions inbasic aqueous solutions.
However, these nanocrystals exhibit a low T2 relaxivity because of
the broad size distribution and defects in the crystal structures.33
In this study, high-quality nanoparticles with uniform size were
synthesized via the thermal decomposition of metal-complex
precursors in an organic phase.14
Although the composition andmagnetocrystalline phase can
be easily controlled, these nanocrystals contained a layer of
hydrocarbons and were dispersed in an organic solvent, which
is not suitable for biomedical applications.40 Therefore, a
number of studies have been carried out for the surface modi-
cation of these high quality nanocrystals. Herein, the ligand
exchanging and amphiphilic micellar coating are two strategies
to stabilize the nanoparticles in water.11,40 For gene delivery, a
positively charged modication is necessary to load negative
nucleotide molecules. To date, polyethylenimine (PEI) is one of
the best available gene delivery materials, which can escape
from intracellular organelles such as endosomes through the
“proton sponge” effect. Recently, HWPEI, for example PEI25K,
has been reported to conjugate on SPIO via the ligand
exchanging method to form MR imaging visible transfection
agents.41–44 These systems could effectively bind with genetic
molecules due to the high charge density of HWPEI. However,
the non-biodegradable property of HWPEI leads to adverse
cytotoxicity.45 Thus, these visible transfection agents are
signicantly limited in clinical applications.6,46 Furthermore,
compared with the HWPEI conjugated monodispersed single
nanocrystals, the T2 imaging sensitivity is greatly improved
when multiple SPIO nanocrystals are gathered together into
nanoclusters.11 Although, the exact reason is not clear, this
phenomenon has been reported in many nanosystems.21,22,33
The cytotoxicity and transfection efficiency strongly correlate
with the molecular weight of PEI. LWPEI exhibits excellent
biocompatibility but poor transfection activities. In the past few
years, the hydrophobic moieties modication of the delivery
systems is believed to be an effective approach to enhance cell
interactions and tissue permeability,47,48 and to improve the
transfection performances.49 Some biocompatible lipophilic
units, for example stearic acid,39 have been used tomodify LWPEI
to enhance its gene transfection efficiency. Amphiphiles form
micelles with a hydrophobic core and hydrophilic shell, which
offer a powerful platform to carry hydrophobic agents. As expec-
ted, the biodegradable amphiphilic Stearic–LWPEI could encap-
sulate the SPIO nanocrystals to form nanoclusters, Stearic–
LWPEI–SPIO, which has strong effects on shortening the T2 time
(Fig. 2). In addition, the highly positive zeta potential of the Stea-
ric–LWPEI-SPIOnanoparticlesplays an important role in resisting
aggregation and forms a compact structure to load nucleic acids
(Fig. 3C andD). Interestingly, the transfected cells showhigh gene
expression andnoticeable signals in theMR images (Fig. 4 and 7).
Altogether, Stearic–LWPEI–SPIO nanoclusters may open up
exciting new horizons for mcDNA delivery and nanomedicine.Conclusions
Multifunctional Stearic–LWPEI–SPIO nanoparticles were
successfully synthesized as MRI visible transfection agentsThis journal is ª The Royal Society of Chemistry 2013using amphiphilic Stearic–LWPEI via a self-assembly method.
These nanoparticles show a high T2 relaxivity and possess many
outstanding features in favor of gene delivery, including high
mcDNA binding capability, protection of mcDNA from enzy-
matic degradation and controlled release of mcDNA in the
presence of polyanionic heparin. Loaded with mcDNA, the
Stearic–LWPEI–SPIO nanoparticles can enhance expression of
luciferase in MCF-7 cells without evidently exhibiting cellular
toxicity. Meanwhile, the transfected cells show higher signal
contrast compared with untreated cells in the T2-weighted
images. Our studies revealed the great potential of these
nanoparticles as MRI visible theranostic nanoparticles for
minicircle plasmid DNA delivery.Acknowledgements
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